Allogene Therapeutics, Inc.
-
Ticker
ALLO
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in South San Francisco, California
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering
…More readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
REPORT RATINGS
4.8 / 5.0 (138)
Allogene Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 138 reviews.
Allogene Therapeutics, Inc.
Most Recent Responsibility Report
MOST RECENT
2023 Environmental, Social & Governance Report
Report Locked. Allogene Therapeutics, Inc. has reached its limit for free report views.
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Allogene Therapeutics, Inc. Sustainability Report, Allogene Therapeutics, Inc. Corporate Social Responsibility Report, Allogene Therapeutics, Inc. CSR Report, Allogene Therapeutics, Inc. Corporate Responsibility, Allogene Therapeutics, Inc. CR Report, Allogene Therapeutics, Inc. Citizenship Report, Allogene Therapeutics, Inc. ESG Report, and Allogene Therapeutics, Inc. Environmental Report online.